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Abstract
Background:  Although most patients with hereditary haemochromatosis have HFE  C282Y
mutations, the lifetime risk to HFE  C282Y homozygotes of developing fatal diseases such as
hepatocellular carcinoma is uncertain. We have carried out a cross-sectional study to determine
the proportion of diagnosed hepatocellular carcinoma patients who are homozygous for the HFE
C282Y mutation; and to estimate the penetrance of this genotype with respect to hepatocellular
carcinoma in East Anglia.
Methods: Tissue biopsies were analysed from 144 cases of hepatocellular carcinoma for HFE
C282Y mutations; the data produced were compared with the frequency of HFE mutations in a
large sample of the local population. Data were also retrieved from the East Anglian Cancer
Intelligence Unit to determine the annual incidence of hepatocellular carcinoma; and from
appropriate life tables.
Results: Eight out of 144 of the cases were homozygous for the HFE C282Y mutation, all 8 cases
were male. 6 of these 8 cases had a previous diagnosis of hereditary haemochromatosis. Male HFE
C282Y homozygotes were more likely to be diagnosed with hepatocellular carcinoma (odds ratio
[OR] = 14, 95% confidence interval [CI] = 5–37). For this population, we estimate that the
penetrance of the HFE C282Y homozygous genotype, with respect to hepatocellular carcinoma,
was between 1.31 % and 2.1% for males and was zero for females.
Conclusion: In this population, we found that only a very small proportion of homozygotes for
the HFE C282Y mutation developed hepatocellular carcinoma. However, individuals with this
genotype have a significantly increased risk of this rare disease relative to those who do not carry
the mutations.
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Background
Hereditary haemochromatosis is an autosomal recessive
genetic condition in which excess iron is absorbed by the
intestine. Individuals with the clinical manifestations of
the disease (which include liver cirrhosis, hepatocellular
carcinoma, diabetes mellitus, cardiomyopathy and
arthropathy) will have accumulated iron over many years
of adult life resulting in progressive tissue damage. Liver
disease is the commonest cause of death of patients with
hereditary haemochromatosis [1,2]. A recent cohort study
of patients diagnosed with haemochromatosis in Sweden
found that at ten years follow-up, the absolute risk of liver
cancer was 6% among men and 1.5% among women [3].
This patient cohort is likely to be at higher risk of liver can-
cer than those HFE C282Y homozygotes who do not dis-
play the signs and symptoms of haemochromatosis [3].
Haemochromatosis is unusual among genetic diseases
because it can easily be treated. Individuals diagnosed and
treated by regular venesection before symptoms of cirrho-
sis occur have a normal life expectancy [4]. The discovery
of mutations in the HFE gene that are present in most
haemochromatosis patients has provided a useful test in
families affected by the disease [5]. Two HFE genotypes
are commonly associated with haemochromatosis:
homozygosity for the C282Y (845A) mutation and com-
pound heterozygosity with the C282Y and H63D (187G)
mutation [5-7].
The high frequency of HFE mutations in the normal pop-
ulation and the availability of a treatment for haemochro-
matosis led to suggestions that population screening for
these mutations would be justified on the basis of both
health and cost [8,9]. The value of screening depends on
the penetrance of the HFE genotypes. Penetrance in this
case can be defined as the frequency with which individu-
als of particular genotypes develop either iron overload or
clinical manifestations.
We have previously studied the penetrance of the HFE
mutations with respect to haemochromatosis disease
manifestations by comparing the predicted birth rate of
HFE  C282Y homozygotes in our study population of
500,000 with the incidence of HFE C282Y-homozygous
patients diagnosed with haemochromatosis, cirrhosis
[10], liver cancer [11], arthritis [12] or diabetes [13]. We
showed that, in this large population, few HFE C282Y
homozygotes (1.4%) were diagnosed with haemochro-
matosis and of the remainder few were diagnosed with
liver disease (2.7% – 8%) or diabetes (0 – 1.3%).
Our findings suggested an unexpectedly low figure for
penetrance which made our estimates for the potential
benefit of genetic screening marginal.
Because of the need for more data to inform decisions
about the value of population screening we have now col-
lected a much larger cohort of hepatocellular carcinoma
(HCC) cases (n = 144) for HFE genotyping. The samples
were drawn from histology archives, collected over a thirty
year period, from the two largest hospitals in East Anglia.
We have used genotyping data from this cross-section of
144 cases and HCC incidence data from the cancer registry
to deduce the incidence of HFE C282Y homozygotes diag-
nosed with HCC annually. We have compared this with
the proportion of the general population who are HFE
C282Y homozygotes and who reach the at-risk age for
HCC annually; this corresponds to the penetrance of HFE
C282Y homozygosity with respect to developing HCC.
Methods
Patient samples; hepatocellular carcinoma cases
The Norfolk and Norwich University Hospital has a catch-
ment area of 500,000 people. 41 suitable HCC cases were
identified from histopathology records from 1974 to
2001 regardless of any previous diagnosis of haemochro-
matosis. 29 cases were from men and 12 were from
women. 28 of these 41 cases from Norwich were included
in our previous studies [10,11].
Addenbrooke's Hospital, Cambridge, is a tertiary referral
centre for hepatic transplantation and referral. Therefore,
cases of liver cancer derive from the hospital's catchment
area of approximately 350,000 individuals and from
other hospitals in East Anglia, and less commonly from
the rest of the U.K. and Italy. For this study, cases were
rejected if the patient's name was Italian to exclude tertiary
referral cases of southern European origin (because of dif-
ferences in the prevalence of HFE mutations). 103 HCC
cases from Addenbrooke's Hospital were identified by
searching files from 1969 to 2000 for cases of HCC regard-
less of any previous diagnosis of haemochromatosis and
included both biopsy cases and explanted livers. 73 cases
were from men and 30 from women.
None of the 103 cases from Addenbrooke's Hospital had
been analysed in the cohort of cases from the Norfolk and
Norwich University Hospital.
Slides from all 144 cases from Norfolk and Cambridge
were reviewed and the presence of HCC confirmed.
Analysis of HFE genotype
Formalin-fixed, paraffin-wax embedded specimens were
retrieved from the histology archives. DNA was extracted
from 10 mm2 of 10 µM tissue sections by sequential
octane and acetone extractions; followed by digestion
overnight at 55°C in 50 µl of 500 µg/ml proteinase K, 10
mM Tris, 1 mM EDTA and 0.5% Tween 20 and subse-
quent incubation for 10 minutes at 96°C.BMC Gastroenterology 2005, 5:17 http://www.biomedcentral.com/1471-230X/5/17
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Analysis of the HFE codon 282 genotypes was carried out
on the PE Biosystems 7700 (Applied Biosystems), using
standard allelic discrimination assay software and Taq-
man Universal PCR Mastermix (Applied Biosystems). In
most cases, 1 µl of template DNA (approximately 50 ng)
was used per assay, the primers and probes are described
in table 1. The annealing temperature in a standard PE
Biosystems 7700 protocol for the assay was 65°C. Four
each of CY heterozygote and CC and YY homozygote and
no DNA controls were included on each 96 well plate. The
primers used amplify a 106 base pair fragment of the HFE
gene and therefore the assay is suitable even for relatively
degraded DNA.
Population data
The control HFE genotype data (see table 2) discussed in
this paper are pooled from two recent publications look-
ing at HFE mutations in the Norfolk and Cambridgeshire
populations [12,14].
The number of C282Y homozygotes reaching the at-risk
age for HCC annually was calculated using data in the
1985–1988 life tables [15].
The annual incidence of HCC in East Anglia between
1970 and 2001 was obtained from the East Anglian Intel-
ligence Unit (cancer registry) [16].
Ethical approval
The analysis of the previously archived tumour and DNA
samples was carried out with local research ethics com-
mittee (LREC) approval from Norwich (NDEC97/090)
and Cambridge (LREC 00/153). All genetic analysis was
carried out on anonymous samples.
Statistical analysis
95% confidence intervals (CI) are exact binomial or, for
ratios, the normal approximation; p values are by Fisher's
exact test.
Results
Analysis of the HFE genotypes
8/144 (5.6 %, 95% CI = 2.4–10.7%) of the cases of HCC
were homozygous for the HFE C282Y mutation. 102 of
the 144 cases were males and all HFE C282Y homozygous
cases were male. Thus 8/102 male HCC cases were HFE
C282Y homozygotes while 9/1508 of the control popula-
tion had this genotype (see table 2). Male HFE C282Y
homozygotes were therefore more likely to be diagnosed
with HCC (OR = 14, 95% CI = 5–37).
The 8 C282Y homozygous cases are described in table 3.
Five of the HFE  C282Y homozygous cases were from
Cambridge; all these had been diagnosed previously with
haemochromatosis. The three other HFE  C282Y
homozygous cases were from Norwich. One of these cases
Table 1: HFE C282Y allelic discrimination assay using taqman probes. The primers and probes used to amplify and detect the portion 
of the HFE gene around codon 282.
Primers and Probes Concentration
forward primer ggctggataaccttggctgtac 300 nM
reverse primer gtcacataccccagatcacaatga 900 nM
mutant probe fam tgctccacctggtacgtatatctctgct 100 nM
wild type probe vic ctccacctggcacgtatatctctgct 100 nM
Table 2: HFE genotypes for codon 282 of HCC cases and control cohorts. Ages in years and numbers (percentages) of cases with each 
genotype.
HCC Patients Controls *
Mean Age 54 a 57
CC (normal) 119 (82.6%) 1331 (88.2%)
CY (heterozygotes) 17 (11.8%) 168 (11.1%) p = 0.34
YY (homozygotes) 8 (5.6%) 9 (0.6%) p = 0.00003
Total Number 144 1508
p values are single tailed probabilities of over-representation of mutant genotypes in HCC patients by Fisher's exact test.
* Norfolk data presented in Willis et al. 2002 [12], Cambridge data presented in Halsall et.al. 2003 [14].
a age data available for only 138/144 cases.BMC Gastroenterology 2005, 5:17 http://www.biomedcentral.com/1471-230X/5/17
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had been diagnosed with haemochromatosis. The
remaining two cases had not been previously diagnosed
with haemochromatosis. Because Addenbrooke's Hospi-
tal is a tertiary referral centre the details of the Norwich
HFE C282Y homozygotes were checked against the Cam-
bridge samples to ensure that there was no duplication.
17/144 (11.8%) cases were heterozygous for the HFE
C282Y mutation. This frequency is essentially the same as
that in the normal population (see table 2).
Population data
C282Y homozygotes reaching the at-risk age for HCC annually
54 was chosen as the at-risk age for HCC because it is the
mean age for presentation with HCC in our cohort. The
proportion of the male population reaching the age of 54
annually (1260 per 100,000) was calculated from the
birth rate (1390 per 100,000) and the proportion surviv-
ing to the age of 54 (lx = 0.912) in the 1985–1988 life
tables [15]. The proportion of the population who are
C282Y homozygotes reaching the age of 54 annually was
calculated from the above figure multiplied by the
observed proportion of C282Y homozygotes in the nor-
mal population: 7.5 per 100,000 [12,14].
The penetrance of the C282Y homozygous genotype with respect to 
HCC
The mean annual incidence of HCC in East Anglia
between 1971 and 2001 was 1.26 per 100,000 males [16].
Our sample allows us to estimate that 7.8% (8 /102 males
in the study) of these were HFE  C282Y homozygotes
(0.099 per 100,000). This figure contrasts with the pro-
portion of the population who are C282Y homozygotes
reaching the at-risk age for HCC annually: 7.5 per 100,000
(see above).
We thus estimate that only 1.31% (95% CI = 0.52–
3.32%) of males homozygous for the HFE C282Y geno-
type are diagnosed and recorded with HCC in this popu-
lation. This corresponds to an estimate of penetrance if
most HCC cases are recorded by the cancer registry.
An alternative method to estimate the normal population
frequency of C282Y homozygosity is to calculate the
square of the C282Y allele frequency (0.0622 = 0.0038).
This figure has a lower standard error, being derived from
the larger number of heterozygotes, but does not take
account of population effects such as non-random mating
or mixing. Repeating the above calculation using this
approach gives an estimate for penetrance of 2.1% (95%
CI = 0.89–4.05%).
In this study we have failed to see any penetrance for the
C282Y homozygous genotype with respect to HCC for
females.
Histology
Slides for cases that were HFE C282Y homozygotes were
reanalysed to examine the background liver abnormalities
in more detail (see table 3). Two of the five C282Y
homozygous samples from Addenbrooke's Hospital were
biopsy specimens, and the remaining three were
explanted livers. Two cases showed significant fibrosis
with prominent linking of many portal tracts by fibrous
bands, but did not show established cirrhosis. The
remaining 3 cases all showed micronodular cirrhosis.
These cases were staged for fibrosis using the method
described by Ishak et.al. [17].
The needle biopsies of 3 C282Y homozygotes from Nor-
wich were analysed, one biopsy consisted of tumour only,
a second showed a minute area of cirrhotic liver and a
third showed minimal fibrosis and was not cirrhotic;
however, there was very little background liver tissue in
this specimen.
All  HFE  C282Y homozygous cases with an adequate
amount of background liver showed siderosis of grades 1
Table 3: Features of HFE C282Y homozygotes. Cases 1–3 were from Norwich, cases 1 and 2 were included in our previous study [11].
Histology (and histological staging of fibrosis) Grade of Siderosis (liver iron) Venesectiona Age# Sex
1 HCC (inadequate for staging) NA* No 66 M
2 HCC, cirrhosis (inadequate for staging) Grade 1 No 70 M
3 HCC (inadequate for staging) Grade 3/4 Yes 64 M
4 HCC, fibrosis (stage 4) Grade 2/3 Yes 64 M
5 HCC, cirrhosis (stage 6) Grade 4 No 73 M
6 HCC, fibrosis (stage 4) Grade 1 Yes 64 M
7 HCC, cirrhosis (stage 6) Grade 4 Not known 63 M
8 HCC, cirrhosis (stage 6) Grade 2/3 Yes 62 M
a Information about previous venesection treatment obtained from histology request forms and reports.
# Age at biopsy.
* Not applicable; only tumour was present in the needle biopsy sample.
HCC, hepatocellular carcinoma.BMC Gastroenterology 2005, 5:17 http://www.biomedcentral.com/1471-230X/5/17
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to 4, with or without a history of venesection treatment
(see table 3).
Discussion
The discovery of the HFE gene in 1996, the high preva-
lence of C282Y mutations, and the morbidity and mortal-
ity associated with untreated hereditary
haemochromatosis have presented molecular diagnostics
with a potentially attractive test for population screening.
Our results show that male HFE  C282Y homozygotes
were more likely to be diagnosed with HCC (OR = 14,
95% CI = 5–37); the HFE C282Y homozygous genotype
could therefore be a significant cause of liver cancer. This
is consistent with the results of longitudinal studies of
haemochromatosis patient cohorts showing that primary
liver cancer is a common cause of death [1-3]. We found
8 HFE C282Y homozygotes in a cohort of 144 HCC cases;
of these 6 had been previously diagnosed with hereditary
haemochromatosis. The genetic data from the 2 other
cases could be interpreted as evidence of undiagnosed
hereditary haemochromatosis leading to HCC. However,
the clinical implication of this finding is uncertain
because these cases were diagnosed with HCC in 1985
and 1990; before which there was less awareness of, and
surveillance for, hereditary haemochromatosis.
Our previous studies have shown that most people with
HFE mutations can survive to old age and do not suffer
from signs of iron overload and haemochromatosis
[18,19]. Large population screens also suggest that only a
minority of HFE  C282Y homozygotes develop clinical
signs and symptoms of iron overload [20-22].
We have now studied a large cohort of HCC patients col-
lected over three decades in a well-defined population.
We estimate that between 1.31% (95% CI = 0.52–3.32%)
and 2.1% (95% CI = 0.89–4.05%) of males homozygous
for the C282Y genotype have diagnosed and recorded
HCC. We found zero penetrance for the HFE  C282Y
homozygous genotype with respect to HCC in women.
We have previously shown that, in Norfolk, only a small
proportion of HFE C282Y homozygotes have been diag-
nosed with and treated with venesection for haemochro-
matosis [23]; therefore pre-cirrhotic management of
haemochromatosis does not explain the low penetrance
described.
These estimates of penetrance in men and women are
higher and lower respectively than our previous com-
bined estimate for men and women of 0.4% (95% CI = 0–
1%) [11]. A combined figure for men and women based
on the data presented here would be slightly higher than
our previous estimate. This difference results mainly from
a lower normal population frequency for the HFE C282Y
allele in the much larger and better age-matched normal
control population presented here.
To estimate the penetrance of the HFE mutations we have
carried out a cross-sectional study of histologically con-
firmed cases of HCC and used cancer registry data that is
reliant on an accurate clinical diagnosis. The main source
of systematic error in estimating penetrance in this study
is likely to be unrecorded or mis-classified HCC. If HCC
cases have not been reported to the cancer registry or were
not accurately classified (e.g. recorded as liver cancer not
otherwise specified) then our calculation of the pene-
trance of these HFE mutations would be an under-esti-
mate.
Any error is likely to be small for two reasons. First, cancer
is a notifiable disease and, 18 months after diagnosis in
East Anglia, ascertainment for all tumours is nearly 100%
complete (Sara Godward, East Anglian Cancer Intelli-
gence Unit; personal communication). Secondly, HCC
usually develops as a long-term complication of cirrhosis
which will often have been detectable several years
beforehand.
The frequency of HFE  C282Y homozygosity in HCC
patients in this study (5.6%) is similar to those seen in
other studies of northern European populations [24,25].
Blanc et al. found that 5.7% of individuals, in a selected
group of French HCC cases developing without cirrhosis,
were HFE C282Y homozygotes [24]. Cauza et al. found
that 3.1% of a cross-section of 162 Austrian HCC cases
were HFE C282Y homozygotes [25]. For males, Austria is
an area with high rates of HCC (10.5/100,000) [26], low
HFE C282Y allele frequencies (5%) [27,28] and similar
life expectancy relative to Britain. Using this limited data
we calculate that this corresponds to a higher penetrance,
at about 10%, of HFE C282Y homozygosity with respect
to HCC in Austria.
Studies from Italy [29,30] and Spain [31] have reported
no  HFE  C282Y homozygotes among cohorts of HCC
patients. However, these were small studies in popula-
tions with low HFE C282Y prevalence. One large study
also found no HFE C282Y homozygotes among a cohort
of French HCC patients [32]. However, the case ascertain-
ment was different to our own; having excluded any
patients suspected to have genetic haemochromatosis
thus precluding comparison with our data.
The expression of the life-threatening clinical manifesta-
tions of haemochromatosis has been shown to be affected
by environmental modifying factors that may also be pop-
ulation specific. Italian haemochromatosis patients who
were older than 55 years, had cirrhosis, a history of high
alcohol consumption and were positive for antibodies forBMC Gastroenterology 2005, 5:17 http://www.biomedcentral.com/1471-230X/5/17
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hepatitis B at diagnosis, had a 150 times higher relative
risk of HCC [33]. Excessive alcohol consumption was also
shown to accentuate the expression of haemochromatosis
in French HFE C282Y homozygotes [34]. One limitation
of this study is that we did not collect data on any environ-
mental risk factors that our patients with HCC were
exposed to; such as high alcohol use and chronic viral
hepatitis. The low mean annual incidence of HCC (1.26
per 100,000 males) in East Anglia over the last three dec-
ades could reflect low exposure to environmental risk
factors.
The value of population screening for HFE C282Y muta-
tions partly depends on the penetrance with respect to the
life-threatening manifestations of haemochromatosis.
The zero penetrance described in this study for female
HFE C282Y homozygotes developing HCC is at odds with
proposals for whole population screening. However, male
HFE  C282Y homozygotes have a high relative risk of
developing HCC. A targeted screening strategy that con-
siders synergistic factors could prove effective for the pre-
vention of this fatal disease, on the grounds of both cost
and health.
Conclusion
• In this U.K. population we have shown that male HFE
C282Y homozygotes are over-represented in a cross-sec-
tion of confirmed HCC cases collected over three decades.
Most of the HFE C282Y homozygotes had been previ-
ously diagnosed with hereditary haemochromatosis; we
therefore found little evidence of undiagnosed haemo-
chromatosis-related HCC over a thirty year period.
• We have used our genotyping data to estimate that
between 1.31% and 2.1% of males homozygous for the
C282Y genotype but no females have diagnosed and
recorded HCC which corresponds to a low estimate of
penetrance.
• The annual incidence of hepatocellular carcinoma in
East Anglia is low relative to other populations which may
reflect low exposure to environmental risk factors for
HCC. In other populations these environmental risk fac-
tors have been shown to synergise with HFE mutations.
Abbreviations
Hepatocellular carcinoma (HCC), odds ratio (OR) confi-
dence interval (CI).
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